Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amedisys (AMED – Research Report), Cytokinetics (CYTK – Research Report) and Coherus Biosciences (CHRS – Research Report).
Amedisys (AMED)
In a report released today, David S Macdonald from Truist Financial maintained a Hold rating on Amedisys, with a price target of $101.00. The company’s shares closed last Wednesday at $93.25, close to its 52-week high of $96.44.
According to TipRanks.com, Macdonald is a 5-star analyst with an average return of
Currently, the analyst consensus on Amedisys is a Hold with an average price target of $101.00, which is an 8.5% upside from current levels. In a report issued on March 4, Leerink Partners also maintained a Hold rating on the stock with a $101.00 price target.
See today’s best-performing stocks on TipRanks >>
Cytokinetics (CYTK)
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Cytokinetics today. The company’s shares closed last Wednesday at $64.63.
According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of
Cytokinetics has an analyst consensus of Strong Buy, with a price target consensus of $94.63, which is a 44.8% upside from current levels. In a report issued on February 28, Goldman Sachs also maintained a Buy rating on the stock with a $85.00 price target.
Coherus Biosciences (CHRS)
Truist Financial analyst Robyn Karnauskas reiterated a Buy rating on Coherus Biosciences today. The company’s shares closed last Wednesday at $2.30, close to its 52-week low of $1.43.
According to TipRanks.com, Karnauskas is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coherus Biosciences with a $10.00 average price target, a 344.4% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $13.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMED:
